Business
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis®
About this update from Zentalis Pharmaceuticals, Inc.
[{"type":"image","alt":"ZENTALIS PHARMACEUTICALS","displaySize":"","headline":null,"caption":"ZENTALIS PHARMACEUTICALS","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/8a2329194a3b92e9d92b6dddf1b01631"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nQzP_GawPdWO8YMImzkdkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8a2329194a3b92e9d92b6dddf1b01631","width":300,"height":87}},"lazy":false},{"type":"text","content":"Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC)","length":146,"tagName":"p"},{"type":"text","content":"Topline data from registration-intent DENALI Part 2 anticipated by year end 2026","length":80,"tagName":"p"},{"type":"text","content":"Strengthened management team to support execution of highly focused strategy","length":76,"tagName":"p"},{"type":"text","content":"$371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027","length":138,"tagName":"p"},{"type":"text","content":"SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced financial results for the year ended December 31, 2024, and highlighted recent corporate accomplishments.","length":387,"tagName":"p"},{"type":"text","content":""Zentalis reported significant progress in the development of azenosertib in 2024 and made important advancements this year. We plan to maintain strong execution on the late-stage development of azenosertib," said Julie Eastland, Chief Executive Officer of Zentalis. “The clinical data we recently presented supports rapid advancement of azenosertib as a monotherapy therapy for patients with Cyclin E1+ PROC, and the continued development of azenosertib in other settings of ovarian cancer and other tumor types. With a sharpened focus on clinical development, and strong cash position into late 2027, Zentalis is well-positioned to execute on our objectives with the goal of bringing azenosertib to patients as quic...